JP2024503425A5 - - Google Patents

Info

Publication number
JP2024503425A5
JP2024503425A5 JP2023542502A JP2023542502A JP2024503425A5 JP 2024503425 A5 JP2024503425 A5 JP 2024503425A5 JP 2023542502 A JP2023542502 A JP 2023542502A JP 2023542502 A JP2023542502 A JP 2023542502A JP 2024503425 A5 JP2024503425 A5 JP 2024503425A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/071382 external-priority patent/WO2022148480A1/zh
Publication of JP2024503425A publication Critical patent/JP2024503425A/ja
Publication of JP2024503425A5 publication Critical patent/JP2024503425A5/ja
Pending legal-status Critical Current

Links

JP2023542502A 2021-01-11 2022-01-11 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用 Pending JP2024503425A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110033695 2021-01-11
CN202110033695.3 2021-01-11
PCT/CN2022/071382 WO2022148480A1 (zh) 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用

Publications (2)

Publication Number Publication Date
JP2024503425A JP2024503425A (ja) 2024-01-25
JP2024503425A5 true JP2024503425A5 (enExample) 2025-01-29

Family

ID=82357142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542502A Pending JP2024503425A (ja) 2021-01-11 2022-01-11 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用

Country Status (7)

Country Link
US (1) US20240059764A1 (enExample)
EP (1) EP4286409A4 (enExample)
JP (1) JP2024503425A (enExample)
KR (1) KR20230147616A (enExample)
CN (1) CN117062908A (enExample)
BR (1) BR112023013790A2 (enExample)
WO (1) WO2022148480A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410371A1 (en) * 2023-02-03 2024-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies against alpha-hemolysin from staphylococcus aureus
CN118480121B (zh) * 2024-05-13 2025-04-01 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BR112013020086B1 (pt) * 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
WO2013013323A1 (en) * 2011-07-28 2013-01-31 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
TWI781130B (zh) * 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
WO2020041394A1 (en) * 2018-08-23 2020-02-27 Trustees Of Tufts College Binding proteins, compositions and methods thereof for neutralization of infection of pathogens having a type iii secretion system
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
CN110563839A (zh) * 2019-08-19 2019-12-13 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b1、应用及试剂盒
CN110526968B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b7、应用及试剂盒
CN110526967A (zh) * 2019-08-19 2019-12-03 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a13、应用及试剂盒
CN110577594B (zh) * 2019-08-19 2021-05-14 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a21、应用及试剂盒
CN110526966B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b6、应用及试剂盒

Similar Documents

Publication Publication Date Title
US20230192819A1 (en) Single domain antibodies for sars-cov-2
JP7328479B2 (ja) 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途
CN112010965A (zh) 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用
JP2024105229A5 (enExample)
CN112225806B (zh) 一种人源抗新型冠状病毒(SARS-CoV-2)的中和活性单克隆抗体
KR20250061718A (ko) 항-인플루엔자 b 바이러스 항체, 인플루엔자 b 바이러스의 검출용 시약 및 키트
CA2983937A1 (en) Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
JP2021524231A5 (enExample)
JP2005528914A5 (enExample)
JP2025506172A5 (enExample)
CN112500481B (zh) 一种人源抗新型冠状病毒的中和活性单克隆抗体
JP2021181450A (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
JP2023506834A5 (enExample)
WO2026012501A1 (zh) 一种抗ngf单克隆抗体及其应用
CN114578066B (zh) 检测β-淀粉样蛋白的产品和方法
CN114594272B (zh) 用于检测β-淀粉样蛋白的产品和方法
CN119798424A (zh) 一种抗尼帕病毒Post-F蛋白的特异性单克隆抗体
KR20230124280A (ko) 메르스 코로나 바이러스의 뉴클레오캡시드 단백질에 특이적인 진단용 항체 및 이의 용도
CN114605532B (zh) 抗β-淀粉样蛋白抗体及其用途
CN114213541B (zh) 一种全能核酸酶的单克隆抗体及其制备方法
JPH0213376A (ja) 緑膿菌に対するモノクローナル抗体、ならびにその調製および使用
KR102421918B1 (ko) 호산구 유래 신경독과 특이적으로 결합하는 단일클론항체 및 이의 용도
CN116096747A (zh) 免疫原性降低型低分子抗体及其制造法
CN119638829B (zh) 抗pspb抗体及其应用
CN117736319B (zh) 一种针对肉毒毒素的纳米抗体